Form 4: Prothena Director Shane Cooke Receives Stock Option Grant

Prothena Corporation director Shane Cooke was granted 27,000 stock options as part of standard equity compensation.

Summary

• Director Shane Cooke received a grant of 27,000 stock options on May 15, 2026.
• The options have an exercise price of $9.76 per share.
• The options are set to expire on May 15, 2036.
• Vesting is scheduled for the earlier of the first anniversary of the grant date or the 2027 annual general meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Vesting is subject to the director maintaining continuous service with the company.

Future Outlook

The options vest in full on the earlier of May 15, 2027, or the date of the 2027 annual general meeting, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, typically occurring annually following shareholder meetings.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of time-based vesting aligns with typical industry benchmarks for director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders face minor potential dilution upon future exercise of these options.

Next Steps

• Director to continue service to satisfy vesting requirements.
• Vesting of options on or before the 2027 annual general meeting.

Key Dates

Keywords

Prothena, PRTA, Director Compensation, Stock Options, Insider Transaction, Biotech